Korean Healthcare Industry
The annual growth is the second highest in drug total healthcare expenditure among OECD members
- 12.7% growth in drug expenditure
- 10.2% in total healthcare expenditure
- Drug Expenditure
- Total Health expenditure
- Ireland12.8%11.4%
- Korea12.7%10.2%
- United States9.6%4.8%
- Australia9.1%4.3%
- Hungary8.3%6.9%
- Greece7.9%4.3%
- Norway7.0%6.5%
- Canada6.4%4.2%
- Finland6.0%4.1%
- Iceland5.8%3.5%
- Austria5.6%5.9%
- Nethrlands5.4%1.8%
- Denmark5.0%4.6%
- Czech4.6%2.8%
- Requblic4.1%5.4%
- Sweden4.0%5.4%
- Luxembourg3.7%5.3%
- Germany3.5%1.8%
- Spain3.4%2.8%
- Swizeriand3.4%2.8%
- Italy3.2%3.2%
- Japan2.2%3.0%
- OECD6.1%4.8%
- Source
- : OECD Health Data 2005
Cause of Death
Main causes of death are Cancer, circulatory diseases, respiratory diseases, etc. Stomach, lung, and liver caners have high incidence in Korea. Globally, lung, stomach and breast cancers are the most prevalent. (Source : KSIS 2007)
- Others 3%
- Digestive system 7%
- Endocrine & Metabolic 8%
- Respiratory system 9%
- Circulatory system 34%
- Cancer 39%
Market Projection for Major Adult Diseases
Combined market for the major adult diseases is expected to grow to US$4 billion In 2012 at annual growth rate of 16%
| Market | 2006 | 2007E | 2012E | CAGR |
|---|---|---|---|---|
| Vasodilator | 142 | 157 | 235 | 11.0% |
| Arteriosclerosis | 269 | 322 | 655 | 23.1% |
| Diabetes | 342 | 390 | 684 | 15.2% |
| Cardiovascular | 566 | 636 | 1,073 | 13.4% |
| Antihypertensive | 775 | 895 | 1,436 | 17.3% |